Search Result

Results for "

macular degeneration

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylin Receptor (1) Amyloid-β (2) Apoptosis (7) Autophagy (2) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (3) Calcium Channel (1) Casein Kinase (1) CCR (1) CGRP Receptor (1) Complement System (12) Drug Derivative (1) Drug Isomer (1) Endogenous Metabolite (5) Estrogen Receptor/ERR (1) FGFR (5) HSP (1) Integrin (2) Interleukin Related (3) Isotope-Labeled Compounds (3) Lipocalin Family (1) Liposome (1) LPL Receptor (1) MetAP (1) Mitochondrial Metabolism (1) MMP (1) MyD88 (1) NF-κB (1) NOD-like Receptor (NLR) (1) Orphan Nuclear Receptor (1) PDGFR (4) Phospholipase (3) Photosensitizer (1) Proteasome (1) Ras (3) Reactive Oxygen Species (ROS) (6) Reference Standards (3) RPE65 (3) Ser/Thr Protease (3) Sigma Receptor (1) Small Interfering RNA (siRNA) (2) Src (2) SRPK (1) Tie (2) TNF Receptor (1) VEGFR (24) Wnt (1) YAP (3) α-synuclein (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (19) Infection (2) Inflammation/Immunology (22) Metabolic Disease (20) Neurological Disease (21)
Oligonucleotides:	Aptamers (5) Liposome (1) siRNA drugs (4) Antisense Oligonucleotides (2) siRNAs (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0146

Verteporfin Maximum Cited Publications 266 Publications Verification CL 318952	YAP Apoptosis Autophagy Photosensitizer	Cancer
Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .

HY-N6947

Lutein 4 Publications Verification Xanthophyll	Endogenous Metabolite Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
Lutein (Xanthophyll) is a carotenoid with reported anti-inflammatory properties. A large body of evidence shows that lutein has several beneficial effects, especially on eye health . Lutein exerts its biological activities, including anti-inflammation, anti-oxidase and anti-apoptosis, through effects on reactive oxygen species (ROS) . Lutein is able to arrive in the brain and shows antidepressant-like and neuroprotective effects. Lutein is orally active .

HY-P3252A

Pegcetacoplan acetate 1 Publications Verification	Complement System	Inflammation/Immunology
Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) .

HY-108801A

Aflibercept (VEGF Trap) 1 Publications Verification	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P9951A

Ranibizumab (anti-VEGF) 1 Publications Verification RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-147080

Avacincaptad pegol sodium ARC1905	Complement System	Others
Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system .

HY-108801

Aflibercept 1 Publications Verification VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-128973

Pyropheophorbide-a 3 Publications Verification	Reactive Oxygen Species (ROS)	Cancer
Pyropheophorbide-a (Ppa) is a photosensitizer used in photodynamic therapy (PDT) for tumors. Pyropheophorbide-a exhibits phototoxic effects on tumor cells, such as cervical cancer cells, and also has anti-lipogenesis activity. Pyropheophorbide-a shows potential for research in the fields of cancer and age-related macular degeneration (AMD). Pyropheophorbide-a derivatives also demonstrate inhibitory activity against tumor cells .

HY-107543

8-pCPT-2′-O-Me-cAMP sodium 1 Publications Verification 8-CPT-2'-O-Me-cAMP sodium	Ras	Cardiovascular Disease
8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP) sodium, an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP sodium activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀ >10 μM). 8-pCPT-2′-O-Me-cAMP sodium stimulates Epac-mediated Ca ²⁺ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP sodium is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP sodium enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .

HY-P99116

Faricimab RG7716; RO-6867461	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

HY-110195

Smurf1-IN-A01 3 Publications Verification A01	HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR	Others Cancer
Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .

HY-163690

HTRA1-IN-1	Ser/Thr Protease	Neurological Disease Inflammation/Immunology
HTRA1-IN-1 is a potent and selective high temperature requirement A serine peptid 1 (HTRA1) inhibitor with an IC₅₀ of 13 nM. HTRA1-IN-1 can be used for the research of HTRA1-related diseases, such as age-related macular degeneration (AMD), osteoarthritis, and rheumatoid arthritis .

HY-150069

UBX1325	Bcl-2 Family Apoptosis	Metabolic Disease
UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .

HY-P99629

Galegenimab FHTR 2163; RG 6147; RO 7171009	Ser/Thr Protease	Neurological Disease
Galegenimab (FHTR 2163) is a humanized monoclonal antibody Fab fragment targeting the HtrA1 trimer. Galegenimab is used in research on age-related macular degeneration (AMD) .

HY-P99905

Efdamrofusp alfa 1 Publications Verification IBI302	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-19720A

Emixustat hydrochloride ACU-4429 hydrochloride	RPE65	Metabolic Disease
Emixustat (ACU-4429) hydrochloride is an orally active RPE65 inhibitor with an IC₅₀ value of 4.4 nM. Emixustat hydrochloride is also a visual cycle modulator, capable of regulating visual cycle activity by inhibiting retinol isomerization, and holds potential for studying vision disorders such as age-related macular degeneration (AMD) .

HY-145628

CM398	Sigma Receptor	Neurological Disease Inflammation/Immunology
CM398 is a highly selective, orally active Sigma-2 receptor ligand with a K_i value of 0.43 nM. CM398 ameliorates age-related macular degeneration. CM398 exerts analgesic effects on visceral pain, inflammatory pain and neuropathic pain. CM398 can be used in research related to age-related macular degeneration, neuropathic pain and inflammatory pain .

HY-P99402

Rinucumab REGN 2176	PDGFR	Cardiovascular Disease Neurological Disease
Rinucumab (REGN 2176) is an anti-PDGFR-β antibody. Rinucumab is used for research on neovascular age-related macular degeneration .

HY-P3204

POT-4 1 Publications Verification AL-78898A	Complement System	Metabolic Disease
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research

HY-148457

Avacincaptad pegol Izervay	Complement System	Infection Neurological Disease Inflammation/Immunology
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA .

HY-19720

Emixustat ACU-4429	RPE65	Metabolic Disease
Emixustat is an orally active RPE65 inhibitor with an IC₅₀ value of 4.4 nM. Emixustat is also a visual cycle modulator, capable of regulating visual cycle activity by inhibiting retinol isomerization, and holds potential for studying vision disorders such as age-related macular degeneration (AMD) .

HY-109561

Pegaptanib sodium EYE001; NX1838	VEGFR	Metabolic Disease Inflammation/Immunology
Pegaptanib sodium is an RNA aptamer with polyethylene glycol modifications, which is directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

HY-12093

MMP408 1 Publications Verification	MMP	Inflammation/Immunology
MMP408 is a selective and orally effective inhibitor of MMP-12 with IC₅₀ values for human, mouse and rat MMP-12 of 2 nM, 160 nM and 3 μM respectively. MMP408 exhibits IC₅₀ value for human MMP-13 of 120 nM, and its activity against other MMPs is weak. MMP408 can alleviate inflammation, fibrosis and tissue remodeling by inhibiting MMP-12. MMP408 can be used in the research of chronic obstructive pulmonary disease and chronic sinusitis with nasal polyps .

HY-P10409

SHLP2 Small humanin-like peptide 2	Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
SHLP2 (Small humanin-like peptide 2) is a small molecule peptide encoded by mitochondrial DNA, belonging to mitochondria derived peptide. SHLP2 has the activity of regulating apoptosis and inhibits cell death. SHLP2 binds to mitochondrial complex 1. SHLP2 improves mitochondrial metabolism by increasing respiration and biogenesis, reducing ROS, and decreasing mtDNA oxidation. SHLP2 also regulated energy homeostasis through the activation of hypothalamic neurons. SHLP2 can be used in the study of diseases related to mitochondrial dysfunction and anti-aging diseases, such as age-related macular degeneration and Parkinson’s disease .

HY-148370

Sefaxersen IONIS-FB-LRx; RG6299; ISIS 696844	Complement System	Others
Sefaxersen (IONIS-FB-LRx) is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen effectively reduces circulating levels of CFB. Sefaxersen can be used for geographic atrophy (GA) research .

HY-148370A

Sefaxersen sodium IONIS-FB-LRx sodium; RG6299 sodium; ISIS 696844 sodium	Complement System	Others
Sefaxersen sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .

HY-10186

TG 100801 1 Publications Verification	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (K_d = 0.5 pM), VEGF-B (K_d = 8 pM), VEGF-C, and PlGF (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .

HY-114653

SRPIN803	Casein Kinase SRPK	Cancer
SRPIN803 is a potent CK2 and SRPK1 dual inhibitor, with IC₅₀s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration .

HY-P99576

Tarcocimab OG1953	VEGFR	Others
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

HY-P1930A

Risuteganib hydrochloride	Integrin	Inflammation/Immunology
Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .

HY-P99298

Lampalizumab RG 7417; TNX 234; Anti-CFD Recombinant Antibody	Complement System	Inflammation/Immunology
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .

HY-W997836

4-Amino-3-hydroxyphenylalanine 4-AHP	Endogenous Metabolite	Cancer
4-Amino-3-hydroxyphenylalanine dihydrochloride (4-AHP) is a photodegradation product of eumelanin. 4-Amino-3-hydroxyphenylalanine dihydrochloride can be used to investigate the development of cutaneous melanoma and age-related macular degeneration .

HY-N0679S

Retinyl acetate-d3 ALK-001; Retinol acetate-d₃; Vitamin A acetate-d₃	Isotope-Labeled Compounds	Metabolic Disease
Retinyl acetate-d₃ (ALK-001) is a deuterated Vitamin A. Retinyl acetate-d₃ can be used for research of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) .

HY-153484A

Bevasiranib sodium	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-116098

Anecortave desacetate AL-4940	Biochemical Assay Reagents	Cancer
Anecortave desacetate (AL-4940) is an angiogenesis inhibitor. Anecortave is indicated for the study of exudative (wet) age-related macular degeneration as well as retinal tumors .

HY-W1048555A

Mal-PEG2000-SCM	Biochemical Assay Reagents	Others
Mal-PEG2000-SCM is a heterobifunctional PEG crosslinker bearing maleimide and succinimidyl carboxymethyl ester functional groups. MMal-PEG2000-SCM conjugates the F3 peptide to nanoparticles: the SCM group reacts with amino groups on the nanoparticle surface to form amide groups, while the MAL group reacts with thiol groups of the F3 peptide to form carbon-sulfur bonds. Mal-PEG-SCM enables unidirectional addition of linkers, ensuring that appropriate functional groups are available for RGD incorporation. Mal-PEG2000-SCM can be used in the development of nanoparticles targeting specific tumor cells .

HY-16467

Squalamine lactate 1 Publications Verification MSI-1256F	Bacterial	Infection Cardiovascular Disease Cancer
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.

HY-15492

AG-13958 1 Publications Verification AG-013958	VEGFR	Cardiovascular Disease
AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .

HY-N13212

Wolfberry Extract	Apoptosis	Neurological Disease Inflammation/Immunology
Wolfberry Extract is the extract of Wolfberry. Wolfberry Extract exhibits antioxidant and anti-inflammatory effects. Wolfberry Extract can be used as a dietary supplement for the research of age-related macular degeneration and inflammatory diseases .

HY-113127

L-Tryptophanamide	Apoptosis	Others
L-Tryptophanamide is a compound discovered in wet age-related macular degeneration research, which has activities related to affecting retinal cell proliferation, apoptosis, necrosis and angiogenesis. In in vitro experiments, L-Tryptophanamide affects the proliferation, apoptosis and necrosis of human retinal pigment epithelial cells, and promotes tube formation and migration of human retinal endothelial cells.

HY-P991415

ASKG-712 AM712	VEGFR Tie	Others
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .

HY-116312

8-pCPT-2′-O-Me-cAMP 8-CPT-2'-O-Me-cAMP	Ras	Cardiovascular Disease
8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP), an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀ >10 μM). 8-pCPT-2′-O-Me-cAMP stimulates Epac-mediated Ca ²⁺ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .

HY-153560

Lp-PLA2-IN-14	Phospholipase	Neurological Disease
Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC₅₀ of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like .

HY-B0146R

Verteporfin (Standard) CL 318952 (Standard)	Reference Standards YAP Apoptosis Autophagy	Cancer
Verteporfin (Standard) is the analytical standard of Verteporfin. This product is intended for research and analytical applications. Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .

HY-136903

SNJ-1945	Calcium Channel Proteasome Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
SNJ-1945 is an orally active Calpain inhibitor that can cross the blood-brain barrier. SNJ-1945 protects rat hearts against cardiac arrest-reperfusion injury by inhibiting the hydrolysis of α-fodrin. SNJ-1945 inhibits VEGF-induced angiogenesis in retinal endothelial cells. SNJ-1945 also protects SH-SY5Y cells from damage induced by MPP+ (HY-W008719) and Rotenone (HY-B1756). SNJ-1945 exhibits anti-inflammatory and neuroprotective activities in a mouse model of multiple sclerosis. SNJ-1945 can be used for the research of cardiovascular, nervous system and inflammatory diseases .

HY-162904

BPU17	Mitochondrial Metabolism	Cardiovascular Disease
BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs). BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent .

HY-10187

TG 100801 Hydrochloride	VEGFR FGFR PDGFR Src	Cancer
TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-P3204A

POT-4 TFA AL-78898A TFA	Complement System	Metabolic Disease
POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .

HY-P1930

Risuteganib	Integrin	Inflammation/Immunology
Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .

Cat. No.	Product Name	Type

HY-W1048555A

Mal-PEG2000-SCM

Biochemical Assay Reagents

Mal-PEG2000-SCM is a heterobifunctional PEG crosslinker bearing maleimide and succinimidyl carboxymethyl ester functional groups. MMal-PEG2000-SCM conjugates the F3 peptide to nanoparticles: the SCM group reacts with amino groups on the nanoparticle surface to form amide groups, while the MAL group reacts with thiol groups of the F3 peptide to form carbon-sulfur bonds. Mal-PEG-SCM enables unidirectional addition of linkers, ensuring that appropriate functional groups are available for RGD incorporation. Mal-PEG2000-SCM can be used in the development of nanoparticles targeting specific tumor cells .

Cat. No.	Product Name	Target	Research Area

HY-P3252A

Pegcetacoplan acetate 1 Publications Verification	Complement System	Inflammation/Immunology
Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) .

HY-P3204

POT-4 1 Publications Verification AL-78898A	Complement System	Metabolic Disease
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research

HY-P10409

SHLP2 Small humanin-like peptide 2	Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
SHLP2 (Small humanin-like peptide 2) is a small molecule peptide encoded by mitochondrial DNA, belonging to mitochondria derived peptide. SHLP2 has the activity of regulating apoptosis and inhibits cell death. SHLP2 binds to mitochondrial complex 1. SHLP2 improves mitochondrial metabolism by increasing respiration and biogenesis, reducing ROS, and decreasing mtDNA oxidation. SHLP2 also regulated energy homeostasis through the activation of hypothalamic neurons. SHLP2 can be used in the study of diseases related to mitochondrial dysfunction and anti-aging diseases, such as age-related macular degeneration and Parkinson’s disease .

HY-16959

CEP dipeptide 1 1 Publications Verification	Peptides	Others
CEP dipeptide 1 is a CEP dipeptide with potent angiogenic activity; mediators of age-related macular degeneration (AMD).

HY-P1930A

Risuteganib hydrochloride	Integrin	Inflammation/Immunology
Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .

HY-P3204A

POT-4 TFA AL-78898A TFA	Complement System	Metabolic Disease
POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .

HY-P1930

Risuteganib	Integrin	Inflammation/Immunology
Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .

HY-P3252AS

Pegcetacoplan-13C3,15N TFA	Isotope-Labeled Compounds Complement System	Inflammation/Immunology
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Cat. No.	Product Name	Target	Research Area	Image

HY-108801A

Aflibercept (VEGF Trap) 1 Publications Verification	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P9951A

Ranibizumab (anti-VEGF) 1 Publications Verification RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-108801

Aflibercept 1 Publications Verification VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P99116

Faricimab RG7716; RO-6867461	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

HY-P99629

Galegenimab FHTR 2163; RG 6147; RO 7171009	Ser/Thr Protease	Neurological Disease
Galegenimab (FHTR 2163) is a humanized monoclonal antibody Fab fragment targeting the HtrA1 trimer. Galegenimab is used in research on age-related macular degeneration (AMD) .

HY-P99905

Efdamrofusp alfa 1 Publications Verification IBI302	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P99402

Rinucumab REGN 2176	PDGFR	Cardiovascular Disease Neurological Disease
Rinucumab (REGN 2176) is an anti-PDGFR-β antibody. Rinucumab is used for research on neovascular age-related macular degeneration .

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (K_d = 0.5 pM), VEGF-B (K_d = 8 pM), VEGF-C, and PlGF (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .

HY-P99576

Tarcocimab OG1953	VEGFR	Others
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

HY-P99298

Lampalizumab RG 7417; TNX 234; Anti-CFD Recombinant Antibody	Complement System	Inflammation/Immunology
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .

HY-P991415

ASKG-712 AM712	VEGFR Tie	Others
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .

HY-P991886

ANX-M1 (Human IgG1)	Complement System	Neurological Disease
ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease ^[1] .

HY-P991416

BAT5906	VEGFR	Others
BAT5906 is a human monoclonal antibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .

HY-P991385

UBX2050	Tie	Neurological Disease Metabolic Disease
UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .

HY-P991418

MW02	VEGFR	Others
MW02 is a human monoclonal antibody (mAb) targeting VEGFA. MW02 can be used in Wet age-related macular degeneration research .

HY-P992142

Vonaprument ANX-007	Complement System	Metabolic Disease
Vonaprument is an intravitreally injected C1q antibody fragment, which is a human monoclonal antibody. Vonaprument is applicable to research related to age-related macular degeneration .

HY-P991534

PF-04382923	Amyloid-β	Neurological Disease
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .

HY-P992151

Sphingomab LT1002	LPL Receptor Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonal antibody and also an inhibitor targeting S1P, with high affinity for S1P and a K_d value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration .

HY-P992126

Remigromig EYE-103; MK-3000	Wnt	Neurological Disease
Remigromig (EYE-103; MK-3000) is a humanized bispecific monoclonal antibody targeting LRP5 and FZD4, suitable for use in research related to macular degeneration .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6947

Lutein 4 Publications Verification Xanthophyll	Animals Classification of Application Fields Terpenoids Whitening Agent Pigments Diterpenoids Cosmetic Research Inflammation/Immunology Disease Research Fields Source Classification Food Research	Endogenous Metabolite Apoptosis Reactive Oxygen Species (ROS)
Lutein (Xanthophyll) is a carotenoid with reported anti-inflammatory properties. A large body of evidence shows that lutein has several beneficial effects, especially on eye health . Lutein exerts its biological activities, including anti-inflammation, anti-oxidase and anti-apoptosis, through effects on reactive oxygen species (ROS) . Lutein is able to arrive in the brain and shows antidepressant-like and neuroprotective effects. Lutein is orally active .

HY-16467

Squalamine lactate 1 Publications Verification MSI-1256F	Infection Cardiovascular Disease Structural Classification Animals Classification of Application Fields Marine natural products Other marine organisms Disease Research Fields Steroids	Bacterial
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.

Cat. No.	Product Name	Chemical Structure

HY-N0679S

Retinyl acetate-d3
Retinyl acetate-d₃ (ALK-001) is a deuterated Vitamin A. Retinyl acetate-d₃ can be used for research of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) .

HY-122129S

Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d6

Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d₆ is deuterium labeled Dotriaconta-14,17,20,23,26,29-hexaenoic acid. Very long chain polyunsaturated fatty acids (VLCPUFA) are present in retina, sperm, and brain. Though little is known of their biosynthesis or functional roles in these tissues, recent studies using the elongation of very long-chain FA-4 protein suggest a unique role for VLCPUFA in retinal development and macular degeneration. Dotriaconta-14,17,20,23,26,29-hexaenoic acid is a C32:6 VLCPUFA whose specific biological actions are largely unknown, but are thought to involve normal photoreceptor cell function in the retina .

HY-P3252AS

Pegcetacoplan-13C3,15N TFA

Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Cat. No.	Product Name		Classification

HY-147080

Avacincaptad pegol sodium ARC1905		Aptamers
Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system .

HY-148457

Avacincaptad pegol Izervay		Aptamers
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA .

HY-109561

Pegaptanib sodium EYE001; NX1838		Aptamers
Pegaptanib sodium is an RNA aptamer with polyethylene glycol modifications, which is directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

HY-148370

Sefaxersen IONIS-FB-LRx; RG6299; ISIS 696844		Antisense Oligonucleotides
Sefaxersen (IONIS-FB-LRx) is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen effectively reduces circulating levels of CFB. Sefaxersen can be used for geographic atrophy (GA) research .

HY-148370A

Sefaxersen sodium IONIS-FB-LRx sodium; RG6299 sodium; ISIS 696844 sodium		Antisense Oligonucleotides
Sefaxersen sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .

HY-153484A

Bevasiranib sodium		siRNAs siRNA drugs
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-177612

AGN-745 AGN-211745; Sirna-027		siRNAs siRNA drugs
AGN-745 is a chemically modified siRNA targeted to VEGFR-1. It is used for the study of Macular degeneration.

HY-153484

Bevasiranib		siRNAs siRNA drugs
Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-177612A

AGN-745 sodium AGN-211745 sodium; Sirna-027 sodium		siRNAs siRNA drugs
AGN-745 sodium is a chemically modified siRNA targeted to VEGFR-1. It is used for the study of Macular degeneration.

HY-177668A

Umedaptanib pegol sodium RBM-007 sodium		Aptamers
Umedaptanib pegol sodium is an anti-fibroblast growth factor-2 (FGF2) aptamer. It is used for the study of neovascular age-related macular degeneration (nAMD).

HY-177668

Umedaptanib pegol RBM-007		Aptamers
Umedaptanib pegol is an anti-fibroblast growth factor-2 (FGF2) aptamer. It is used for the study of neovascular age-related macular degeneration (nAMD).

HY-185390

Verteporfin liposome Liposomal verteporfin		Liposome
Verteporfin liposome is a liposome-encapsulated form of Verteporfin (HY-B0146). Verteporfin is a photosensitizer used in photodynamic therapy to eliminate abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin liposome prolongs drug circulation time and provides slow release, allowing the drug to accumulate in newly formed blood vessels.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

macular degeneration

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products